🔍 Concall Decoded

🎙 Management Tone Tracker Confident Specific → Stable 5 quarters analysed

Q2 2025

Confident Specific

Management used phrases like 'excellent set of H1 results', 'strong double-digit adjusted diluted EPS growth', and 'raising our adjusted diluted EPS full-year forecast'. Specific numbers were provided throughout (e.g., +11.4% HTU IMS growth, +26% US Zyn off-take, +14.9% organic OI growth). The tone was upbeat and forward-looking with quantified guidance.

Q3 2025

Confident Specific

Management repeatedly used positive language like 'excellent results', 'very strong performance', 'record quarterly level', and provided specific figures (e.g., $3 billion quarterly smoke-free gross profit for the first time, adjusted diluted EPS $2.24). They openly discussed elevated commercial spending and one-off investments, showing confidence in their strategy.

Q4 2025

Confident Specific

Management repeatedly used phrases like 'outstanding year', 'strongest growth since 2011', and 'exceed all targets', and provided specific numbers (e.g., 12.8% SFP volume growth, 15% EPS growth, 40%+ operating margin) to underscore consistent outperformance.

Q1 2026

Confident Specific

Management used phrases like 'strong start', 'outstanding growth', 'impressive progress', and 'exceeded expectations', indicating confidence. Specific numbers (e.g., +10% OI growth, $1.96 EPS) reinforced the positive tone.

Q2 2026 latest

Confident Specific

Emmanuel led with a string of quantified beats ('+8% organic net revenue', '+11% operating income', '+14% EPS') and repeated phrases like 'very strong', 'excellent first half', and 'we approach the remainder of 2026 with confidence.' He framed the unchanged guidance not as caution but as a deliberate choice to reinvest incremental strength into U.S. ZYN.

Guidance Reliability Pending · <3Q data

Investor Lens

Investment thesis is modestly stronger after this call: H1 beat expectations, Q2 showed +8% organic revenue, +11% organic OI and +15% EPS, and management kept FY guidance only because it is choosing to reinvest upside into U.S. ZYN. That signals confidence in underlying international momentum and puts the U.S. at the center of the next leg. The ZYN story is improving with Ultra, MRTP claims and broader portfolio, but management did not quantify offtake or promotional aggressiveness, and Q3 faces a tough comparison from September 2025 promotion (~250M pouches). Japan remains a monitored risk despite resilience, with another October excise step likely to create phasing noise. Watch next quarter for ZYN consumer response to new variants, the margin impact of H2 U.S. investment, and delivery against Q3 EPS guidance of $2.20-$2.25 with $0.08 currency drag.

AI-generated concall tone analysis · Updated 2026-08-14 · Not investment advice

🔒

Premium Feature

AI-generated 10-section company profile — business model, financials, strengths, risks & management quality

Upgrade to Premium

Already a member? Log in

📐

3-Statement Financial Model

Bear / Base / Bull projections · DCF fair value · Reverse-DCF

Open Model →

🎙 Management Tone Confident Specific → Stable 5 quarters Full tone analysis in Intelligence →

Good quarter Investor Presentation One-Pager? Q2 2026

Revenue

$11.2B

+10.4% YoY reported; +7.6% organic

Operating Income

$4.8B

+12% YoY in dollars; +11% organic (adjusted)

Operating Margin

Close to 42% (H1)

+0.6pp YoY in dollars; +0.4pp organic (H1)

Adjusted Diluted EPS

$2.20

+15.2% YoY; +13.6% excluding currency

What Went Right

Q2 net revenue exceeded $11B for the first time, with organic growth +7.6% and adjusted diluted EPS up 15.2% to $2.20.
International smoke-free continued to power results: H1 organic net revenue grew +13.7% and gross profit +16.9%, with IQOS adjusted IMS up +5.1% in Q2 despite Japan/Poland headwinds — excluding those, +10%.
Combustibles outperformed: Q2 cigarette shipments rose +1.1%, international combustible gross profit grew +8% organically, and full-year cigarette volume decline was narrowed to around 2-3%.

What to Watch

Japan remains volatile: Q2 IQOS adjusted IMS fell 3.4% as pantry-loading reversed, with further disruption expected around the October excise increase.
U.S. ZYN competition/price premium persisted — retail value share is ~57%, and Q3 compares against ~250 million pouches of one-off September 2025 promotional volume.
Management is deliberately stepping up U.S. investment in H2, with SG&A phasing and higher spend expected to pressure second-half profit growth.

Management Guidance

Full-year 2026: organic net revenue growth of +5% to +7%; organic operating income growth of +7% to +9%; currency-neutral adjusted diluted EPS growth of +7.5% to +9.5%.
Adjusted diluted EPS forecast raised only for currency to $8.26-$8.41, reflecting an ~$0.15 currency tailwind.
Q3 2026: adjusted diluted EPS expected at $2.20-$2.25, including an unfavorable currency impact of $0.08; Q3 organic revenue growth expected in mid-single digits with modest operating margin expansion.
Full-year operating cash flow guidance stands at about $13.5B.

Investor Lens

The thesis looks stronger after this call: PMI delivered better-than-expected Q2 results, with smoke-free growth accelerating internationally and combustibles beating expectations. Management held full-year guidance only because it is reinvesting more aggressively in the U.S. ZYN platform, rather than because of deterioration. Japan's excise-driven volatility and U.S. competitive share are the key swing factors; if new ZYN variants and marketing regain momentum, full-year growth could come in at the top end or higher.

From investor presentation · AI-generated analysis · Not investment advice

🔒

Premium Feature

Investor Presentation One-Pager — quarterly highlights, what went right/wrong & management guidance

Upgrade to Premium

Already a member? Log in

📈 STRONG Strong Q2: revenue above $11B, adjusted EPS $2.20, up 15%.

Revenue

Q2 net revenue reached $11.2B, up 10.4% in dollars and 7.6% organically — the first time quarterly revenue surpassed $11B. International smoke-free net revenue grew 11.8% organically, while international combustibles contributed +6.1% organic growth.

Profitability

Adjusted diluted EPS grew 15.2% to $2.20, or 13.6% excluding currency; reported diluted EPS declined 7.7% to $1.80 due to a non-cash impairment of the RBH equity investment. Adjusted operating income rose ~11% organically and ~12% in dollar terms to $4.8B.

Margins

H1 adjusted operating margin was close to 42%, up 40 basis points organically and 60 basis points in dollars. International smoke-free H1 gross margin expanded 190 basis points to 70%, while total H1 international gross margin reached 68.6%, up 160 basis points on pricing, scale and smoke-free mix.

Balance Sheet

No debt/cash balance sheet detail was discussed in the call. Management reiterated full-year operating cash flow guidance of ~$13.5B and highlighted continued commitment to progressive dividends and shareholder returns.

Key Risks

Management flagged Japan's October excise-driven volatility and the reversal of prior pantry-loading, as well as U.S. competitive pressure on ZYN from higher-strength/moist products. The increased H2 U.S. investment and challenging Q3 ZYN year-over-year comparison were also highlighted as near-term headwinds.

Outlook

Full-year guidance was maintained: organic revenue +5% to +7%, organic operating income +7% to +9%, and currency-neutral EPS +7.5% to +9.5%, with adjusted EPS now $8.26-$8.41. Q3 EPS is guided at $2.20-$2.25 with mid-single-digit organic revenue growth and modest margin expansion.

Generated by AI · Q2 2026 results · Not investment advice

🔒

Free Account Required

Create a free Finmagine account to access Finmagine™ Scorecard.

See how this company scores across 5 dimensions — Financial Health, Growth Prospects, Competitive Position, Management Quality, and Valuation — powered by 30+ computed ratios.

Create Free Account Log In

🔒

Premium Feature

Upgrade to Finmagine Premium to unlock Ask AI.

Get 25 expert AI analysis templates — Business KPIs, Comprehensive, Forensic Governance, Peer Comparison, Risk-Reward, Full Research Report, IPO Decoder, Red Flag Detector, and more — ready to paste into ChatGPT, Claude, Gemini, or Perplexity.

Upgrade to Premium Create Free Account

🔒

Premium Feature

Upgrade to Finmagine Premium to unlock Peer Comparison.

Compare this company side-by-side against its sector peers with financial metrics, ratio benchmarking, and relative performance across all key dimensions.

Upgrade to Premium Create Free Account

✓ 📞 Earnings Call Transcripts (5 quarters) submit a missing quarter

🔍

🔎 See cross-company document search → ?

📞 Earnings Call Transcripts (5)

Q2 2026 Q2 2026 2026-07-22

Q2 and H1 saw strong organic growth in revenue, operating income, and EPS, driven by smoke-free products and robust combustible performance. Guidance remains unchanged as increased U.S. investment is planned for H2, especially behind ZYN and IQOS ILUMA.

Q1 2026 Q1 2026 2026-04-22

Q1 2026 saw robust growth in smoke-free products, strong pricing, and margin expansion, driving double-digit gains in adjusted operating income and EPS. Guidance for 2026 is reaffirmed, with continued investment in innovation and sustainability, despite regulatory and macroeconomic uncertainties.

Q4 2025 Q4 2025 2026-02-06

Reported strong 2025 results with double-digit EPS and operating income growth, driven by robust smoke-free product expansion and margin gains. 2026 guidance anticipates continued top- and bottom-line growth despite tax and regulatory headwinds, with renewed medium-term targets and strong cash flow supporting shareholder returns.

Q3 2025 Q3 2025 2025-10-21

Q3 saw record results driven by strong smoke-free product growth, margin expansion, and robust U.S. ZYN performance, despite elevated investment and promotional costs. Full-year guidance was raised for EPS and cash flow, with continued focus on deleveraging and shareholder returns.

Q2 2025 Q2 2025 2025-07-22

H1 2025 saw record smoke-free net revenues, double-digit EPS growth, and margin expansion, with strong performances from IQOS, Zyn, and Veev. Full-year guidance was raised for EPS, revenue, and cash flow, while robust pricing and cost efficiencies offset modest combustible volume declines.

🔒

Premium Feature

Upgrade to Finmagine Premium to unlock Catalyst Timeline.

Every result, order win, insider trade, ECS update, earnings-call, and SEC announcement for this company — in one chronological lane.

Upgrade to Premium Create Free Account

🔒

Premium Feature

Upgrade to Finmagine Premium to unlock Full Report.

Read the complete Finmagine™ investment research report — comprehensive fundamental analysis, business model assessment, competitive positioning, and investment recommendation.

Upgrade to Premium Create Free Account

⚠️ Important Disclaimers — Please read without fail.

Investment Risk:
Investing in securities, including US equities and ETFs, involves inherent risks including the potential loss of principal. All investments are subject to market fluctuations, economic conditions, regulatory changes, and other factors that may affect their value. Past performance is not indicative of future results. This analysis is provided for informational and educational purposes only and should not be construed as investment advice under any circumstances.

No Investment Recommendation:
This analysis does not constitute, nor should it be interpreted as, an offer, solicitation, or recommendation to buy, sell, or hold any securities or financial products. Investors are strongly advised to conduct their own independent research and due diligence and to consult with a licensed financial advisor or an SEC-registered investment adviser before making any investment decisions, taking into account their individual financial situation, risk tolerance, and investment objectives.

Not SEC-Registered:
Finmagine is not registered as an investment adviser with the U.S. Securities and Exchange Commission (SEC) or any state securities authority. Nothing on this platform constitutes investment advice as defined under the Investment Advisers Act of 1940.

Conflict of Interest Disclosure:
The author and/or analyst may currently hold or have previously held positions in the securities discussed. Any such positions are not intended to influence the objectivity or independence of the analysis. This research is produced independently and is not sponsored, endorsed, or commissioned by any company or institution.

Information Sources:
The analysis is based on publicly available information including SEC filings (10-K, 10-Q), annual reports, management commentary, and publicly available financial data. Information is believed to be accurate as of the date of publication but may be subject to change without notice. Readers are encouraged to independently verify all information before acting upon it.

Forward-Looking Statements:
This analysis may contain forward-looking statements, forecasts, or projections that are inherently subject to risks, uncertainties, and assumptions. Actual results may differ materially from those expressed or implied. Finmagine does not undertake any obligation to update such statements in the future.

Limitation of Liability:
The content is provided "as is" without any warranties, express or implied. Finmagine expressly disclaims any liability for errors, omissions, or any losses incurred as a result of reliance on the information provided. Readers assume full responsibility for their investment decisions.

📊 Analysis Methodology